[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:anti-ds-dna-antibody":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Anti-ds DNA Antibody",23,19,[8,16,22,29,35,42,49,54,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06570798","A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",[12],"Phase 2","RECRUITING","2026-08-26T02:15:10.362237Z","2026-07-24T01:27:14.890537Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07053800","Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)",[12],"2026-08-26T02:15:42.447052Z","2026-07-05T05:32:16.729991Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07201558","Study Evaluating Safety, Tolerability, PK\u002FPD of Surovatamig in Adult RA or SLE Participants",[26],"Phase 1","2026-08-26T02:17:36.611194Z","2026-07-05T05:32:16.666464Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT05268289","Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +\u002F- V",[12],"2026-08-26T02:18:22.309547Z","2026-05-29T15:36:40.174644Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT07430306","A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus",[39],"Phase 3","2026-08-26T02:17:06.985283Z","2026-05-13T02:55:06.705839Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT06121297","RESET-SLE: A Phase 1\u002F2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus",[46],"Phase 1\u002FPhase 2","2026-08-26T02:16:04.914942Z","2026-05-05T02:43:29.164988Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":14,"content_modified":53},"NCT06581198","A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE\u002FLN)",[12],"2026-05-05T02:43:28.728724Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT07225387","Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial",[58],"Phase 4","2026-08-26T02:15:58.452248Z","2026-05-05T02:43:27.813070Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06625671","A Phase 1\u002F2a Study of DB-2304 in Healthy Adults and SLE Participants",[46],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:27.671925Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06737380","UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients",[26],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:27.646843Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06613360","A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",[26],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.314554Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06977724","A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)",[26],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:26.921745Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06617325","A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",[39],"2026-08-26T02:16:42.787115Z","2026-05-05T02:35:31.934489Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07409181","A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)",[12],"2026-08-26T02:18:49.989941Z","2026-05-05T02:35:31.877860Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06557265","A Phase 1\u002F2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)",[46],"2026-08-26T02:18:58.958025Z","2026-06-17T02:29:30.003977Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06916806","A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.",[26],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.362747Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06434363","Phase I\u002FII Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders",[46],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.675534Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT07237659","Phase 1a\u002Fb Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA",[26],"2026-08-26T02:18:20.384845Z","2026-07-24T01:27:14.902192Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07175285","A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants",[],"2026-08-26T02:17:48.768272Z","2026-05-13T02:55:06.670897Z",{"nct_id":128,"title":129,"phases":130,"status":131,"updated_at":71,"content_modified":132},"NCT07729995","BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease",[26],"NOT_YET_RECRUITING","2026-07-30T01:46:14.459181Z",{"nct_id":134,"title":135,"phases":136,"status":137,"updated_at":47,"content_modified":138},"NCT06518668","A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus",[26],"ENROLLING_BY_INVITATION","2026-07-05T03:45:20.249630Z",{"nct_id":140,"title":141,"phases":142,"status":137,"updated_at":143,"content_modified":144},"NCT07038447","A Study of KITE-363 in Participants With Refractory Autoimmune Diseases",[26],"2026-08-26T02:15:11.740957Z","2026-06-16T05:54:07.853790Z",{"nct_id":146,"title":147,"phases":148,"status":149,"updated_at":150,"content_modified":151},"NCT05648500","A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus",[39],"ACTIVE_NOT_RECRUITING","2026-08-03T02:17:17.775722Z","2026-05-05T02:43:28.643616Z"]